This protein interacts with the Epidermal growth factor receptor to promote the growth of normal epithelial cells.
Within that range, quantitative information on the EGFR density in the cell membrane can be retrieved based on the shift in resonant frequency of the plasmonic particles.
The O'Reilly Factor | The X Factor (UK) | Microphthalmia-associated transcription factor | The X Factor | Fear Factor | receptor | Max Factor | LDL receptor | Receptor (biochemistry) | The X Factor (TV series) | Continuous erythropoietin receptor activator | B-cell activating factor | GABA receptor | Epidermal growth factor receptor | Psi Factor: Chronicles of the Paranormal | NMDA receptor | Astro Boy: Omega Factor | The Limits to Growth | Sensory receptor | receptor (biochemistry) | metabotropic glutamate receptor | growth | Economic growth | 5-HT2A receptor | VLDL receptor | twist transcription factor | The X Factor (U.S.) | The X Factor (UK TV series) | The X Factor (UK series 2) | The Omega Factor |
AP26113 has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).
Cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer (mCRC), in combination with chemotherapy, and as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
In addition, some ER may associate with cell membranes by attachment to caveolin-1 and form complexes with G proteins, striatin, receptor tyrosine kinases (e.g., EGFR and IGF-1), and non-receptor tyrosine kinases (e.g., Src).
The term "juxtacrine" was originally introduced by Anklesaria et al. (1990) to describe a possible way of signal transduction between TGF alpha and EGFR.
Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
It is believed that estrogen promotes growth by up-regulating IGF-1, EGFR, TGF-beta1, TGF-beta3 and PDGF, and promotes aberrant survival of leiomyoma cells by down-regulating p53, increasing expression of the anti-apoptotic factor PCP4 and antagonizing PPAR-gamma signalling.